Function
Smad2 is an intracellular mediator of TGF-beta family and activin type 1 receptor. Smad2 mediate TGF-beta signaling to regulate cell growth and differentiation. Smad2 is released from cytoplasmic retention by TGFbeta receptor-mediated phospho-rylation. The phosphorylated Smad2 then forms a heterodimeric complex with Smad4, and this complex translocates from cytoplasm into nucleus. By interacting with DNAbinding proteins, Smad complexes then positively or negatively regulate the transcription of target genes.
Homology
With the other members of the Darfwin/Smad family.
Implicated in

Disease
Colorectal cancers Oncogenesis
Smad2 was proposed to be a tumor suppressor gene that may function to disrupt TGF-beta signaling. Inactivating mutations in Smad2 have been found in various cancer including colorectal carcinomas. The majority of tumor-derived mutations cluster in the carboxy-terminal MH2 domain, and some of these have been shown to disrupt TGF-beta signaling by blocking receptor-dependent phospho-rylation or by preventing heterodimeric interactions between Smads. A mutation at position 133 in the amino-terminal MH1 domain has also been associa-ted with colorectal carcinoma. Nevertheless, loss of Smad2 activation and/or expression was related to occur in less than 10% of colorectal cancers. SMAD2 (mothers against decapentaplegic homolog 2 (Drosophila)) Saffroy R et al. Atlas Genet Cytogenet Oncol Haematol. 2004; 8(3) 250 To be noted Smad2 gene has also been found alterated in lung carcinomas, cervical carcinomas and hepatocellular carcinomas.
